Voyager Therapeutics (VYGR) Accumulated Expenses (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Accumulated Expenses data on file, last reported at $7.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 22.99% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 million (down 22.99% YoY), and the FY2025 full-year result was $9.1 million, up 34.64% from the prior year.
• Accumulated Expenses eased to $7.0 million in Q1 2026, from $9.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $16.8 million in Q4 2023 to a low of $2.2 million in Q1 2024.
• A 5-year average of $7.7 million and a median of $7.0 million in 2026 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 74.45% in 2022 and jumped 302.71% in 2025, its largest moves.
• Tracing VYGR's Accumulated Expenses over 5 years: stood at $7.8 million in 2022, then jumped by 115.24% to $16.8 million in 2023, then sank by 59.86% to $6.8 million in 2024, then soared by 34.64% to $9.1 million in 2025, then fell by 23.31% to $7.0 million in 2026.
• Business Quant data shows VYGR's Accumulated Expenses at $7.0 million in Q1 2026, $9.1 million in Q4 2025, and $15.0 million in Q3 2025.